HomeBUSINESS
BUSINESS

Kyowa Kirin’s Burosumab Gains European Panel Backing for Conditional Approval
(Dec.19.2017)

Kyowa Hakko Kirin and its US partner Ultragenyx Pharmaceutical said on December 15 that their anti-FGF23 monoclonal IgG1 antibody burosumab (KRN23) obtained a recommendation from a key European panel for its conditional approval for X-linked hypophosphatemia (XLH) ...
(LOG IN FOR FULL STORY)

News Calendar